

Edgar Filing: BIOENVISION INC - Form AW

BIOENVISION INC
Form AW
June 07, 2004

Bioenvision, Inc.
509 Madison Avenue, Suite 404
New York, New York 10022

June 7, 2004

VIA EDGAR
United States Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Re: Bioenvision, Inc..
Request to Withdraw Post-Effective Amendment
and Post-Effective Amendment #2 to Registration
Statement on Form S-3 to Form SB-2 (File No. 333-97443)

Ladies and Gentlemen:

Pursuant to Rule 477 of the Securities Act of 1933, as amended (the "Securities Act"), Bioenvision, Inc. a Delaware corporation (the "Registrant"), respectfully makes application to the Securities and Exchange Commission (the "Commission") to withdraw (i) the Post-Effective Amendment to Registration Statement on Form S-3 to Form SB-2 together with all exhibits, filed with the Commission on January 12, 2004 (the "Post-Effective Amendment #1") (File No. 333-97443) and (ii) the Post-Effective Amendment No.2 to Registration Statement on Form S-3 to Form SB-2 together with all exhibits, filed with the Commission on April 2, 2004 (the "Post-Effective Amendment #2") (File No. 333-97443). Neither the Post-Effective Amendment #1 nor the Post-Effective Amendment #2 have been declared effective by the Staff.

We are requesting the withdrawal of the Post-Effective Amendment #1 and the Post Effective Amendment #2 per the suggestion of the Commission. No securities were sold in connection with either the Post-Effective Amendment #1 or the Post-Effective Amendment #2. The Post Effective Amendment #2 was converted into a Registration Statement on Form SB-2 (File No. 333-115816), which was filed with the Commission on May 24, 2004.

Please direct any questions you have regarding Registrant's request to withdraw the Post-Effective Amendment #1 and the Post-Effective Amendment #2 to David Luci at (212) 750-6660 or to Kristen Dunker, counsel of the Registrant, at (212) 318-6467 or via email at kristendunker@paulhastings.com.

Sincerely,

/s/ David P. Luci

David P. Luci
Director of Finance and General Counsel
Bioenvision, Inc.